“Treating Rare Diseases” – Soligenix, Inc.’s (Nasdaq: SNGX) ($SGNX) interview with Dr. Christopher J. Schaber, Chairman, President, and CEO.

0
116

Soligenix, Inc.’s (Nasdaq: SNGX) ($SNGX) Chairman, President and Chief Executive Officer, Dr. Christopher J. Schaber, is on this week’s New to The Street Show. Talking with TV Host Jane King from the Nasdaq MarketSite studio, he explains the Company’s business as a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company has a robust pipeline contained within its two business segments. The Company’s Specialized BioTherapeutics segment focuses on developing products for orphan diseases and areas of unmet medical need in oncology and inflammation. Their Public Health Solutions segment develops heat-stable vaccines and therapeutics for military and civilian applications in ricin exposure, emerging and antibiotic-resistant infectious diseases, and viral diseases, including Ebola, Marburg, and COVID-19. Dr. Schaber talks about HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) and expects to file a NDA (New Drug Application) in Q4, targeting FDA market authorization approval sometime in the second half of 2023. The Company’s Public Health Solutions segment has received approximately $80M to date from the US Government, non-dilutive funding, used to develop and deploy heat-stable vaccines for biodefense and emerging infectious diseases. SNGX’s Sudan Ebola vaccine has shown remarkable results in non-human primate studies. The heat-stable vaccines in development can withstand 100-degree temperatures without efficacy degradation. Heat stability is a must for the successful deployment of vaccines in areas of the world that lack adequate refrigeration sites for vaccine storage. Dr. Schaber talks about the Company’s work in finding a treatment for Psoriasis, another unmet medical need. The active ingredients in its CTCL treatment also appear to be effective in treating those with Psoriasis. He told viewers to expect the Company to initiate a Phase 2 clinical study for the Psoriasis treatment in December 2022. The on-screen QR code is available during the show; download or visit Soligenix, Inc. (Nasdaq: SNGX) ($SGNX) – https://www.soligenix.com/.

To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv

Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet

Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/

Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/

Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet

About New to the Street: https://newtothestreet.com/

Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list